gene therapy

4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products

4D Molecular Therapeutics (4DMT), a leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, today

4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Productscurechm2019-08-28T17:46:09-05:00

Nightstar Announces First-Ever Phase 3 Choroideremia Gene Therapy Trial

Nightstar Therapeutics has announced the initiation of the company’s STAR Phase 3 registrational trial to study the safety and efficacy of NSR-REP1 in

Nightstar Announces First-Ever Phase 3 Choroideremia Gene Therapy Trialcurechm2019-08-28T17:45:45-05:00

Nightstar Therapeutics raises $75 Million in IPO to fund Pivotal Phase 3 Gene Therapy Study

Nightstar Therapeutics held it’s Initial Public Offering on Thursday September 28th, raising $75 Million which will be used to advance the company’s gene therapy

Nightstar Therapeutics raises $75 Million in IPO to fund Pivotal Phase 3 Gene Therapy Studycurechm2019-08-28T17:45:57-05:00